Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy

耳穴按摩治疗化疗引起的神经病变

• 批准号: 10684707
• 负责人: Constance Margaret Johnson
• 金额: $ 65.65万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10684707
• 关键词: Acupressure; Acupuncture Therapy; Adherence; Affect; Aftercare; American Society of Clinical Oncology; Analgesics; Anti-Inflammatory Agents; Basal Ganglia; Biological Markers; Bortezomib; Brain; Cancer Patient; Cancer Survivor; Cells; Characteristics; China; Clinical; Clinical Trials; Data; Demographic Factors; Dose; Ear; Ear Acupuncture; Ecological momentary assessment; Equilibrium; Esthesia; Ethnic Origin; Europe; Exercise; Fatigue; Fingers; Functional Magnetic Resonance Imaging; Functional disorder; Gender; Goals; Hand; Health Care Costs; Image; Inflammation; Inflammatory; Interferon Type II; Interleukin-1 beta; Interleukin-2; Interleukin-6; Intervention; Late Effects; Licensing; Macrophage; Malignant Neoplasms; Measures; Mediating; Monitor; Needles; Neurons; Numbness; Opioid; Outcome; Pain; Pain Threshold; Pain management; Participant; Patient Self-Report; Patients; Peripheral Nervous System; Pharmaceutical Preparations; Physical Function; Placebo Effect; Placebos; Plasma; Platinum; Provider; Psychophysics; Quality of life; Race; Randomized, Controlled Trials; Recommendation; Regulation; Reporting; Resources; Self Management; Sensory; Sensory Thresholds; Severities; Signal Transduction; Sleep; Specificity; Stimulus; Survival Rate; Symptoms; TNF gene; Taiwan; Testing; Time; Toes; Vinca Alkaloids; active method; afferent nerve; cancer therapy; chemotherapy; chemotherapy induced neuropathy; cognitive control; cytokine; design; duloxetine; effective therapy; efficacy evaluation; executive function; expectation; experience; fall risk; foot; functional disability; improved; indexing; innovation; morphine equivalent; neuroimaging; opioid overuse; opioid use; pain inhibition; pain perception; pain relief; persistent symptom; primary endpoint; primary outcome; secondary outcome; sex; side effect; skills; smartphone application; taxane; tool; treatment as usual

More than 60% cancer patients experience chemotherapy-induced neuropathy (CIN), a severe side effect of chemotherapy (including platinum drugs, vinca alkaloids, taxanes and/or bortezomib). CIN may cause treatment delays, dose reductions, or discontinuation of therapy which can affect survival rates. With improved cancer treatments and longer survival, the late effects of CIN continue to produce a significant burden in up to 50% of cancer survivors who are suffering from CIN 6 years after treatment, with a 1.8-fold increased risk of falls. CIN continues to cause significant functional disability, negatively impacts quality of life, and significantly demands high health care costs and resource use. We propose to test auricular point acupressure (APA)—a non-invasive and nonpharmacological patient managed strategy—as an innovative solution for CIN. APA is developed from auricular acupuncture, which is an invasive (using needles) and passive treatment (administered by a licensed practitioner). APA is a non-invasive and active treatment for patients with pain. It involves needleless acupuncture-like stimulation of ear points. Small seeds are taped on specific ear points by a skilled provider and patients press on the seeds to stimulate ear points three times daily, three minutes per time, for a total of nine minutes per day to achieve pain relief. APA provides pain relief within 1–2 minutes after ear stimulation and sustains pain relief for one month after a 4-week APA intervention. APA is popular in Taiwan, China, and Europe. Though its use is sparse in the U.S., a limited number of clinical trials have supported APA in pain management. This study will provide vital information to gain a comprehensive understanding of underlying mechanism of APA on CIN and provide strong impetus for including APA as part of CIN management in clinical settings.

超过 60% 的癌症患者会出现化疗引起的神经病变 (CIN)，这是化疗药物的严重副作用 化疗（包括铂类药物、长春花生物碱、紫杉烷类和/或硼替佐米）。 CIN 可能会导致 治疗延迟、剂量减少或停止治疗可能会影响生存率。和 随着癌症治疗方法的改进和生存期的延长，CIN 的后期影响继续产生显着的影响 高达 50% 的癌症幸存者在治疗 6 年后患有 CIN，负担增加了 1.8 倍 跌倒的风险增加。 CIN 继续导致严重的功能障碍，对患者的质量产生负面影响 生命，并极大地需要高昂的医疗保健费用和资源使用。 我们建议测试耳穴穴位按压 (APA)——一种非侵入性且非药物治疗的患者 管理策略——作为 CIN 的创新解决方案。 APA是从耳针疗法发展而来的 是一种侵入性（使用针头）和被动治疗（由有执照的执业医师进行）。 APA 是一个 对疼痛患者进行非侵入性积极治疗。它涉及无针针灸般的刺激 耳点。由熟练的提供者将小种子贴在特定的耳点上，患者按压 每天用种子刺激耳穴3次，每次3分钟，每天总共9分钟 达到缓解疼痛的目的。 APA 可在刺激耳朵后 1-2 分钟内缓解疼痛，并持续缓解疼痛 为期 4 周的 APA 干预后持续一个月。 APA 在台湾、中国和欧洲很受欢迎。虽然其 在美国使用很少，有限数量的临床试验支持 APA 在疼痛管理中的应用。 这项研究将为全面了解潜在机制提供重要信息 APA 对 CIN 的影响，并为将 APA 作为临床环境中 CIN 管理的一部分提供了强有力的推动力。